Part or Boehringer’s broader clinical program targeting diabetic retinal disease, BI 1815368 is the fourth investigational compound from Boehringer Ingelheim’s Eye Health portfolio to advance to a ...

At the 2025 Annual Meeting, I had the privilege of 1 I have been working on over the past year—exploring how retinal imaging might help detect early signs of Alzheimer disease (AD), especially in ...

Modern Retina’s recent Case-Based Roundtable focused on next-generation treatments for retinal disease that provide advanced care for neovascular age-related macular degeneration (nAMD) and diabetic ...

Biotechnology company Nanoscope Therapeutics recently announced the formation of Vision Advisory Committee (VAC). 1 VAC is “a group of renowned experts in retina treatment and commercialization,” a ...

Christine Kay, MD, presented interim 1-year data from a phase 1/2 study of an investigational gene therapy (OPGx-LCA5; Opus Genetics) for LCA5-related Leber congenital amaurosis at the Clinical Trials ...

Breye Therapeutics announced the successful completion of its phase 1b clinical trial of an oral therapy, danegaptide, for early treatment of non-proliferative diabetic retinopathy (NPDR) and ...

Clinical-stage biotechnology company PYC Therapeutics recently held a type B meeting with the US Food and Drug Administration (FDA) to discuss requirements for a new drug application (NDA) for the ...

Robert Collier said, “success is the sum of small efforts, repeated day in and day out.” So, as we approach the busiest retina meeting season, remember each small effort and give these pearls a try.

Treatment provided suboptimal control of the nAMD in the right eye, with a visual acuity (VA) of 20/40 and central subfield thickness (CST) of 397 µm; the left eye VA was 20/30, and the CST was 297 µm ...

Ahead of the Clinical Trials at the Summit (CTS) meeting in Las Vegas, Nevada, Victor Gonzalez, MD, shared an overview of his presentation. Dr. Gonzalez is a trial investigator in the REMAIN follow-up ...

Newsletter Keep your retina practice on the forefront—subscribe for expert analysis and emerging trends in retinal disease management.